MNGIE is a dubious disease in the field of genetic metabolism, clinical performance is complex and often involves multi-systematic fatigue. Early identification and standardized diagnosis are essential for improving prognosis. Diagnosis of the disease requires a combination of clinical performance, imaging, laboratory testing and pathological activation.
The platform can assist in bringing together a team of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many previously difficult-to-treat genetic metabolic disorders have been significantly improved. Treatment needs to be closely monitored for efficacy and adverse reactions, adapted to the timely schedule depending on the change in the disease.
Multidisciplinary collaboration (MDT) is particularly important for the integrated management of MNGIE for mitochondrial neuropathic gastrointestinal and cerebrovascular disease. 2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment programs; 3.
Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.